GSK4396687
Vaccine
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
No clinical trials on ClinicalTrials.gov
No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.
No registered studies found. Not yet ingested, or none registered.
Competitive landscape
This drug's own stage for COVID-19: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| GSK4396687: this drug | Stage not on record | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1806 (Tofidence) | Approved | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Elasomeran (Spikevax) | Approved | Vaccine | SARS-CoV-2 spike protein | Reliable signal | No reviewed efficacy summary in this indication | |
| Tocilizumab (Actemra / RoActemra) | Approved | Monoclonal antibody | IL-6 receptor | Partial signal | NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36) | |
| Azvudine (FNC) | Phase 3 | Small molecule | HIV reverse transcriptase | not yet graded | No reviewed efficacy summary in this indication | |
| Ibuzatrelvir | Phase 3 | Small molecule | SARS-CoV-2 3CL protease | not yet graded | No reviewed efficacy summary in this indication | |
| Levilimab (Ilsira) | Phase 3 | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Masitinib | Phase 2 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.